Frances M. Bashore

This paper develops NanoBRET assays for PAK1 and its mutant in primary neurons to evaluate inhibitor target engagement.

This study develops and characterizes a potent and cell-active inhibitor of TTBK1 and TTBK2, with selectivity and potential therapeutic applications for neurodegenerative diseases.

The paper compares cell-free and cellular assays for kinase inhibitor selectivity, finding divergent results and identifying new kinase interactions in cells.

The paper develops a chemical probe, SGC-CK1γ-1, for the CK1γ subfamily, showing potent and selective inhibition of CK1γ kinases, WNT signaling, and HCMV replication.

This study shows that BRD4 degraders are less effective than BET inhibitors in reactivating latent HIV in CD4+ T-cells, highlighting the importance of BRD4's role in disrupting 7SK and P-TEFb.

The paper develops a NanoBRET assay to study SYK gain-of-function variants in live cells and demonstrates inhibitor efficacy against these variants.

The paper identifies and characterizes a chemical probe for CDKL2, demonstrating its selectivity and biological impact in neurons and cancer cells.

The paper identifies two covalent inhibitors that disrupt the interaction between SYK's tandem SH2 domains and FCER1G phospho-ITAM, potentially beneficial for Alzheimer's disease therapy.

This study identifies MSN and CD44 as potential therapeutic targets for Alzheimer's disease by developing inhibitors of their interaction through structural and chemical screening.

The paper develops specific CDKL5 inhibitors that do not affect GSK3β activity and shows their effects on synaptic function and LTP in rat hippocampal slices.